FreeCME

Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC

CME: 0.5

Target Audience

The target audience for this educational initiative is oncologists, oncology NPs, PAs, and nurses, pulmonologists, pulmonology NPs and PAs, pathologists, and pharmacists.

Program Overview

Are you up to date on the role of immunotherapy in the setting of non-small cell lung cancer (NSCLC)? In this educational activity, experts Heather Wakelee, MD, and Meghan Ramsey, MD, explore how to select patients with early-stage resectable NSCLC who may derive benefit from immunotherapy and how to recommend immunotherapy for NSCLC according to clinical data and patient-specific factors. This immersive activity will challenge your clinical decision-making specific to NSCLC through two patient case scenarios developed to demonstrate pathways to improving patient care for patients with NSCLC.

Learning Objectives

Upon completion of this educational activity, learners should be better able to:

  • SELECT patients with early-stage resectable NSCLC who may derive benefit from immunotherapy
  • RECOMMEND immunotherapy as a component of multimodal therapy in early-stage resectable NSCLC according to recent clinical trial data and patient preferences

Post a comment to this article